Olipudase alfa (Xenpozyme®). HTA ID: 23014

Assessment Status Rapid Review Complete
HTA ID 23014
Drug Olipudase alfa
Brand Xenpozyme®
Indication As an enzyme replacement therapy for the treatment of non-Central Nervous System (CNS) manifestations of Acid Sphingomyelinase Deficiency (ASMD) in paediatric and adult patients with type A/B or type B.
Assessment Process
Rapid review commissioned 08/03/2023
Rapid review completed 31/03/2023
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of olipudase alfa compared with the current standard of care.